Funding for this research was provided by:
AbbVie
Article History
Received: 27 October 2023
Accepted: 7 February 2024
First Online: 11 March 2024
Declarations
:
: Larry Culpepper has served as an advisor or consultant for AbbVie Pharmaceuticals, Eisai Pharmaceuticals, Takeda, and Supernus Pharmaceuticals; owns stock in M-3 Information, LLC, and has received royalties from UpToDate and Oxford University Press and receives payment from Physicians Postgraduate Press as Editor in Chief of the<i> Primary Care Companion for CNS Diseases</i>. Ashley Martin was an employee of Cerner Enviza at the time of this study, which was funded by AbbVie to perform the analysis. She is currently employed at BluePath Solutions (Los Angeles, CA). Nadia Nabulsi and Mousam Parikh are employees of AbbVie and may hold stock.
: This study was exempt from Ethics Committee approval and institutional review because it is a retrospective analysis which used anonymized and de-identified data certified as fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Allergan (prior to its acquisition by AbbVie) obtained permission to access and use the 2019 National Health and Wellness Survey data used in the analysis through licensing agreements.